Visa enkel post

dc.contributor.authorCahlin, Birgitta Johansson
dc.date.accessioned2016-05-23T08:06:03Z
dc.date.available2016-05-23T08:06:03Z
dc.date.issued2016-05-23
dc.identifier.isbn978-91-628-9782-6 (print)
dc.identifier.isbn978-91-628-9783-3 (PDF)
dc.identifier.urihttp://hdl.handle.net/2077/42337
dc.description.abstractThe aim of this thesis was to explore aspects of pharmaceutical intervention in temporomandibular disorders (TMDs) and bruxism. Sleep bruxism is a movement disorder that signals disturbed sleep and constitutes a significant health problem due to TMDs, headache and tooth wear. In Study I, medication was reviewed in patients referred for specialist treatment for TMDs. Female patients with myofascial pain used significantly more psychoactive medication, including antidepressants, tranquilizers, sedatives and hypnotics, compared with matched controls. These findings support other research demonstrating an overrepresentation of the diagnoses depression, anxiety, stress and sleep problems among TMD patients. Study II compared the effect of oral glucosamine sulfate on osteoarthritis in the temporomandibular joints with that of placebo. Glucosamine sulfate appeared to improve signs and symptoms over time, but it was not significantly superior to placebo. In Study III, the dopamine agonist, pramipexole, was investigated in severe sleep bruxism confirmed by polysomnographic/electromyographic monitoring. The severity of sleep bruxism was not reduced compared with control conditions, indicating that the involvement of the dopamine system in bruxism is less likely. In Study IV, the effects of botulinum toxin injections in the masticatory muscles, compared with placebo injections, were evaluated in subjects with cerebral palsy and bruxism. No significant differences between active and control injections in terms of subjective or objective oral functions could be observed at group level. In conclusion, the results were negative with respect to the evaluated pharmacologic remedies for TMDs and bruxism. There is a relative lack of controlled studies in this area. Considering the pronounced negative impact on quality of life that has been reported for these conditions, it should be an important task continuously to evaluate putative pharmacologic therapies in TMDs and bruxism.sv
dc.language.isoengsv
dc.relation.haspartI. Johansson Cahlin B, Samuelsson N, Dahlström L. Utilization of pharmaceuticals among patients with temporomandibular disorders: a controlled study. Acta Odontol Scand. 2006;64(3):187-92. ::PMID:: 16809198sv
dc.relation.haspartII. Cahlin BJ, Dahlström L. No effect of glucosamine sulfate on osteoarthritis in the temporomandibular joints – a randomized, controlled, short-term study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112(6):760-6. ::doi::10.1016/j.tripleo.2011.06.012sv
dc.relation.haspartIII. Cahlin BJ, Hedner J, Dahlström L. A randomised, open-label, cross-over study of the dopamine agonist, pramipexole, in patients with sleep bruxism.sv
dc.relation.haspartIV. Cahlin BJ, Lindberg C, Dahlström L. Cerebral palsy and bruxism: effects of botulinum toxin injections – a randomized, controlled trialsv
dc.subjecttemporomandibular disorderssv
dc.subjectsleep bruxismsv
dc.subjectglucosamine sulfatesv
dc.subjectpramipexolesv
dc.subjectdopamine agonistsv
dc.subjectbotulinum toxinsv
dc.subjectcerebral palsysv
dc.titleMedication in temporomandibular disorders and bruxismsv
dc.typeTexteng
dc.type.svepDoctoral thesiseng
dc.gup.mailbirgitta.johansson-cahlin@vgregion.sesv
dc.type.degreeDoctor of Philosophy (Odontology)sv
dc.gup.originUniversity of Gothenburg. Sahlgrenska Academysv
dc.gup.departmentInstitute of Odontology. Department of Behavioral and Community Dentistrysv
dc.gup.defenceplaceFredagen den 10 juni 2016, kl 9.00, Hörsal Arvid Carlsson, Academicum, Medicinaregatan 3, Göteborgsv
dc.gup.defencedate2016-06-10
dc.gup.dissdb-fakultetSA


Filer under denna titel

Thumbnail
Thumbnail

Dokumentet tillhör följande samling(ar)

Visa enkel post